Baxter Shares Face Pivotal Moment Ahead of Earnings Release

Baxter International is preparing to disclose its full-year 2025 financial results, navigating a complex landscape marked by operational headwinds. The company's strategic adjustments, including workforce reductions, are under scrutiny as stakeholders assess whether these measures can counterbalance recent disappointing revenue trends.

Despite facing significant challenges, Baxter has attracted notable institutional interest. Investment firm FMR LLC reported acquiring a 6.8% stake in the company around the turn of the year. This vote of confidence comes as the stock shows signs of stabilization in 2026, having advanced approximately 11% since the start of the year. However, the broader picture remains challenging, with shares still down nearly 38% over the trailing twelve-month period.

• Previous Close (Thursday): €18.49
• 12-Month Change: -37.65%
• Year-to-Date (YTD) Change: +11.09%

The market’s attention is now firmly fixed on Thursday, February 12, 2026, when Baxter will release its detailed Q4 and annual report before U.S. markets open. The subsequent conference call with analysts is expected to center on the company’s guidance for 2026 and the progress being made in stabilizing its supply chain operations.

Supply Chain Disruptions Prompt Restructuring

A major factor influencing Baxter’s current position is severe disruption at its North Cove facility, which is responsible for producing roughly 60% of the intravenous (IV) solutions supplied across the United States. Production at this critical site was hampered by Hurricane Helene in September 2024.

Should investors sell immediately? Or is it worth buying Baxter?

The aftermath of the storm led to practical adjustments in the clinical use of infusion solutions across U.S. healthcare providers. This shift in market demand has compelled Baxter to realign its manufacturing capacity. In response, the company conducted a review of its production network, resulting in the confirmed elimination of about 90 positions at its Marion site on February 5. Market observers interpret this streamlining effort as a move to protect profitability in a difficult environment.

Quarterly Performance and Revised Outlook

An examination of the third quarter of 2025 reveals contrasting results. Baxter’s adjusted earnings per share (EPS) of $0.69 surpassed market expectations. Conversely, revenue of $2.84 billion fell short of estimates.

The company’s performance was affected not only by weather-related events but also by difficulties within its Novum IQ pump portfolio. These combined pressures led management to revise its full-year forecast. The upcoming report will clarify how these operational adjustments have influenced the final quarter and whether the steps taken are setting a foundation for recovery.